<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285866</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 19/02_S-REAL</org_study_id>
    <nct_id>NCT04285866</nct_id>
  </id_info>
  <brief_title>Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.</brief_title>
  <acronym>S-REAL</acronym>
  <official_title>Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, observational, multicentre, one-arm, non-comparative, and&#xD;
      retrospective study.&#xD;
&#xD;
      The study is based on the collection of data about the patients treated with Durvalumab after&#xD;
      chemoraditherapy in the real world. The patients participating in this non-interventional&#xD;
      study will not receive treatment in relation to the study. The primary objective is to assess&#xD;
      affectiveness of durvalumab in patients treated in real-life settings by evaluating&#xD;
      Progression Free Survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung Cancer represent approximately 13% of total cancer diagnoses worldwide and continues to&#xD;
      be the leading cause of cancer-related mortality. Stage III represents between 25-30% of&#xD;
      NSCLC and the majority of them are unresectable. The standard treatment in unresectable&#xD;
      patients was chemoradiotherapy consurrently if possible.&#xD;
&#xD;
      The PACIFIC study is a phase III study to evaluate the efficacy and safety of durvalumab as a&#xD;
      sequential therapy concurrent platinum-based chemotherapy and thoracic RT. The study was&#xD;
      positive for both primary endpoints progression-free survival and overall survival. After&#xD;
      that, it was decided to open an early acces programme ti provide acces to durvalumab for&#xD;
      patients with locally advanced, unresectable NSCLC (stage III) tho have not progressed&#xD;
      following chemoradiation.&#xD;
&#xD;
      This observational study is based on the collection of data about the patients treated with&#xD;
      Durvalumab after chemoraditherapy in the real world.&#xD;
&#xD;
      The study will include all patients who have participated in the EAP between 1 September 2017&#xD;
      up to 21 December 2018 and have received at least 1 dose of durvalumab.&#xD;
&#xD;
      The primary objective is to assess affectiveness of durvalumab in patients treated in&#xD;
      real-life settings by evaluating Progression Free Survival. Other secondary objectives are:&#xD;
&#xD;
      To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating&#xD;
      1-year survival rate, to describe adverse events of special interests, to stimate time and&#xD;
      sites of disease progression or relapse in metastatic setting, to describe details on&#xD;
      durvalumab treatment, to describe demographic and clinical characteristics of stage III&#xD;
      unresectable NSCLC patients treated with Durvalumab, to describe previous chemoradiotherapy&#xD;
      strategy, to describe the baseline staging status, to further assess subsequent treatments&#xD;
      pattern at the time of disease progression including duration of therapy and type of therapy,&#xD;
      and to explore healthcare resource utilization while on durvalumab treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months</time_frame>
    <description>To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating 1-year survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe adverse events of special interest (AESIs)</measure>
    <time_frame>From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months</time_frame>
    <description>To describe AESIs leading to treatment temporary interruption or permanent discontinuation of durvalumab, or which require interventions of concomitant use of corticosteroids, immunosupressants and/or endocrine therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and site of disease progression or relapse</measure>
    <time_frame>From date of the first dose of durvalumab received to the date of disease progression, assessed up to 60 months</time_frame>
    <description>To estimate time and sites of disease progression or relapse in metastatic setting.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Small Cell Lung Cancer (SCLC)</condition>
  <arm_group>
    <arm_group_label>Durvalumab Group</arm_group_label>
    <description>Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab after chemoradiotherapy</description>
    <arm_group_label>Durvalumab Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have parcipated in the EAP between 1 September 2017 up to 21 December 2018&#xD;
        and have received at least 1 dose of durvalumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically or cytologically documented diagnosis of NSCLC with&#xD;
             a locally advanced, or locally recurrent, unresectable (stage III) disease (according&#xD;
             to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8).&#xD;
&#xD;
          2. Age ≥ 18 years at time of study Entry&#xD;
&#xD;
          3. Patients must have been treated with chemotherapy and radiotherapy concurrently or&#xD;
             sequentially and shown no progressive disease following chemoradiation&#xD;
&#xD;
          4. Patients must have been enrolled in durvalumab EAPs between 1 September 2017 and 21&#xD;
             December 2018.&#xD;
&#xD;
          5. Patients must have been treated with at least one dose of durvalumab within the EAP&#xD;
&#xD;
          6. Alive patients must have signed, dated and IRB/EC-approved written informed consent*&#xD;
             form in accordance with regulatory and institutional guidelines. This must be obtained&#xD;
             before the performance of any protocol-related procedures that are not part of normal&#xD;
             subject care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alive patients who do not want to sign and date an IRB/IEC-approved written informed&#xD;
             consent form.&#xD;
&#xD;
          2. Patients who were accepted in the EAP, but did not receive treatment.&#xD;
&#xD;
          3. Patients treated with durvalumab in clinical studies prior to the index date (first&#xD;
             dose of durvalumab received within the EAP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis León, MD</last_name>
      <phone>(+34) 981 95 00 00</phone>
      <email>luis.leon.mateos@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Luis León, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noemí Villanueva, MD</last_name>
      <phone>34 985 10 80 00</phone>
      <email>eesteban@seom.org</email>
    </contact>
    <investigator>
      <last_name>Noemí Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Doménech, MD</last_name>
      <phone>34 934 97 88 00</phone>
      <email>mdomenechv@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Marta Doménech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Muñoz, MD</last_name>
      <phone>34 938 42 50 00</phone>
      <email>smborrajo5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Silvia Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laia Vilà, MD</last_name>
      <phone>34 93 723 10 10</phone>
      <email>lvila@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Laia Vilà, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta López, MD</last_name>
      <phone>34 942202515</phone>
      <email>marta.lopezbrea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Barba</last_name>
      <phone>34 932 91 90 00</phone>
      <email>abarba@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Andrés Barba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delvys Rodríguez, MD</last_name>
      <phone>+34 928 441738</phone>
      <email>delvysra@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Delvys Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco García, MD</last_name>
      <phone>34 871202000</phone>
      <email>franciscojavier.garcianavalon@hsll.es</email>
    </contact>
    <investigator>
      <last_name>Francisco García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xabier Mielgo, MD</last_name>
      <phone>34 916219256</phone>
      <email>xmielgo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xabier Mielgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa María Villatoro, MD</last_name>
      <phone>34 951 97 66 69</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rosa María Villatoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Gil, MD</last_name>
      <phone>34 948 25 54 00</phone>
      <email>igbazo@unav.es</email>
    </contact>
    <investigator>
      <last_name>Ignacio Gil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <state>País Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Paredes, MD</last_name>
      <phone>+34 943006032</phone>
      <email>alfredo.paredeslario@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Alfredo Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayram Padilla, MD</last_name>
      <phone>34 922602020</phone>
      <email>airampadillaalvarez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ayram Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De La Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corina Escoín, MD</last_name>
      <phone>34 962 54 28 00</phone>
      <email>escoin_cor@gva.es</email>
    </contact>
    <investigator>
      <last_name>Corina Escoín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Ángeles Sala, MD</last_name>
      <phone>34 944 00 60 00</phone>
      <email>MARIAANGELES.SALAGONZALEZ@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Mª Ángeles Sala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Alonso-Jáudenes, MD</last_name>
      <phone>34 981 178000</phone>
      <email>guillermo.alonso.curbera@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Guillermo Alonso-Jáudenes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massutí, MD</last_name>
      <phone>+34 96 593 35 13</phone>
      <email>bmmassuti@seom.org</email>
    </contact>
    <investigator>
      <last_name>Bartomeu Massutí, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Mar Parc de Salut de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Álvaro Taus, MD</last_name>
      <phone>34 932483137</phone>
      <email>ataus@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Álvaro Taus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isidoro Barneto, MD</last_name>
      <phone>+34 968 35 90 00</phone>
      <email>isidoroc.barneto.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Isidoro Barneto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Teresa Delgado, MD</last_name>
      <phone>34 958 02 30 00</phone>
      <email>maitechu22@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>María Teresa Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Enrique Chara, MD</last_name>
      <phone>34 949 20 92 00</phone>
      <email>lucho_chara@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Luis Enrique Chara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Laura Ortega, MD</last_name>
      <phone>953220306</phone>
      <email>analauraortega@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Laura Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Miguel Sánchez, MD</last_name>
      <phone>+34 91 5202585</phone>
      <email>jmiguelst@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José Miguel Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Álvarez, MD</last_name>
      <phone>34 915 86 80 00</phone>
      <email>rosa.alvarez.al@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rosa Álvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Garrido, MD</last_name>
      <phone>+34913368263</phone>
      <email>pilargaridol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Garrido</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Aguado, MD</last_name>
      <phone>+34 91 300 30 00</phone>
      <email>carlos.aguado84@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Aguado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Dómine, MD</last_name>
      <phone>+34 91 5504800</phone>
      <email>manueldomine@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Dómine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabel del Barrio, MD</last_name>
      <phone>34 917 56 78 00</phone>
      <email>adelbarrio@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Anabel del Barrio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Sereno, MD</last_name>
      <phone>34 911 91 40 00</phone>
      <email>mariasereno75@gmail.com</email>
    </contact>
    <investigator>
      <last_name>María Sereno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Fírvida, MD</last_name>
      <phone>34 988385471</phone>
      <email>jose.luis.firvida.perez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>José Luis Fírvida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Bellido, MD</last_name>
      <phone>34 923291100</phone>
      <email>lbellido@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Lorena Bellido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Esteban, MD</last_name>
      <phone>34 921 41 91 00</phone>
      <email>besteban@saludcastillayleon.es</email>
    </contact>
    <investigator>
      <last_name>Beatriz Esteban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabé, MD</last_name>
      <phone>34 955 01 32 79</phone>
      <email>reyesbernab@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Reyes Bernabé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Álvarez, MD</last_name>
      <phone>34 925 26 92 00</phone>
      <email>ruthalvarez21@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruth Álvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Juan-Vidal, MD</last_name>
      <phone>+34 961 24 40 00</phone>
      <email>juan_osc@gva.es</email>
    </contact>
    <investigator>
      <last_name>Oscar Juan-Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael López, MD</last_name>
      <phone>34 983 420003</phone>
      <email>rafalopezcastro@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dolores Isla, MD</last_name>
      <phone>976765746</phone>
      <email>lola.isla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dolores Isla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ángel Artal, MD</last_name>
      <phone>34 976 76 55 00</phone>
      <email>aartalc@salud.aragon.es</email>
    </contact>
    <investigator>
      <last_name>Ángel Artal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced small cell lung cancer</keyword>
  <keyword>SCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>durvalumab after chemotherapy</keyword>
  <keyword>real world data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

